Evidence map›Paper›PMID 34992382›Full record

ArticleOncoTargets and therapy2021

Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel

Gang Shen, Yinping Du, Jifang Shen, Junling Zhang, Xihua Xia, Mengli Huang, Wenxiang Shen

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Gang Shen *Department of Radiology, The Affiliated Kunshan Hospital of Jiangsu University, Kunshan, People's Republic of China.
Yinping Du *Department of Radiology, The Affiliated Kunshan Hospital of Jiangsu University, Kunshan, People's Republic of China.
Jifang ShenDepartment of Radiology, The Affiliated Kunshan Hospital of Jiangsu University, Kunshan, People's Republic of China.
Junling ZhangThe Medical Department, 3D Medicines, Inc., Shanghai, People's Republic of China.ORCID 0000-0003-3518-7584
Xihua XiaThe Medical Department, 3D Medicines, Inc., Shanghai, People's Republic of China.
Mengli HuangThe Medical Department, 3D Medicines, Inc., Shanghai, People's Republic of China.ORCID 0000-0003-0169-7906
Wenxiang ShenDepartment of Oncology, The Affiliated Kunshan Hospital of Jiangsu University, Kunshan, People's Republic of China.
Jiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is still the leading cause of morbidity and mortality by cancer among men, according to the latest epidemiological data in China. Anaplastic lymphoma kinase (

Indexed as

adverse eventsceritinibnon-small cell lung cancerPTH2R-ALK

Identifiers

PMID34992382
PMCPMC8711735
OpenAlexW4200597798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.